Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.44 |
| ▸ | PYGM | P11217 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083262 | 0.83 | CTSA (0.45) | NPC1RAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL620738 | 0.83 | L3MBTL1 (0.58) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL3945417 | 0.82 | ALDH1A1 (0.51) | KDM4CRAB9AALDH1A1L3MBTL1GRM5 | |
| SCHEMBL3735813 | 0.82 | GRM5 (0.49) | RAB9AALDH1A1GRM5TSHRPYGL | |
| SCHEMBL1054692 | 0.80 | KDM4C (0.58) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL6072144 | 0.80 | L3MBTL1 (0.55) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL620675 | 0.80 | KDM4C (0.54) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL306105 | 0.80 | SMN1; SMN2 (0.62) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL25368936 | 0.79 | KDM4C (0.54) | KDM4CNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL31132286 | 0.79 | KDM4C (0.54) | KDM4CNPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| EP-3316884-A1 | THERAPEUTIC INHIBITORY COMPOUDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| EP-2903989-A1 | PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-20150218172-A1 | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| WO-2014053967-A1 | PYRROLO[2,3-D]PYRIMIDINE TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KDM4C 723/4885NPC1 959/4885RAB9A 2909/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KDM4C 723/4885NPC1 959/4885RAB9A 2909/4885 |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | KDM4C 934/4885NPC1 2090/4885RAB9A 2612/4885 |
| US-10023557-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | KDM4C 723/4885NPC1 959/4885RAB9A 2909/4885 |
| US-20150218172-A1 | Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors | MUSK, DMPK, TPM3 | KDM4C 3604/4885NPC1 4431/4885RAB9A 2661/4885 |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | KDM4C 723/4885NPC1 959/4885RAB9A 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.